De Maio Flavio, Bianco Delia Mercedes, Delogu Giovanni
Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy.
Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie - Sezione di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022021. doi: 10.4084/MJHID.2022.021. eCollection 2022.
Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at the end of 2019, a number of medications have been used to treat the infection and the related Coronavirus disease - 19 (COVID-19). Some of the administered drugs were tested or used in practice only on the basis of biological plausibility; a promising strategy was to target the host immune response, with host directed therapies (HDTs), to reduce systemic hyperinflammation and hypercytokinemia responsible for additional tissue damage. We summarize the treatments against SARS-CoV-2 and underline their possible effects on () infection. Both SARS-CoV-2 and respiratory infections impair the host's immune response. Furthermore, little research has been conducted on the impact of medicaments used to counteract COVID-19 disease in patients with Latent Tuberculosis Infection (LTBI). A number of these drugs may modulate host immune response by modifying LTBI dynamic equilibrium, favoring either the host or the bacteria.
自2019年底严重急性呼吸综合征冠状病毒2（SARS-CoV-2）出现以来，已有多种药物用于治疗该感染及相关的冠状病毒病-19（COVID-19）。一些使用的药物仅基于生物学合理性在实践中进行了测试或使用；一种有前景的策略是通过宿主导向疗法（HDTs）针对宿主免疫反应，以减少导致额外组织损伤的全身过度炎症和高细胞因子血症。我们总结了针对SARS-CoV-2的治疗方法，并强调了它们对（）感染可能产生的影响。SARS-CoV-2和呼吸道感染都会损害宿主的免疫反应。此外，对于用于治疗潜伏性结核感染（LTBI）患者的COVID-19疾病的药物影响，几乎没有进行过研究。其中一些药物可能通过改变LTBI动态平衡来调节宿主免疫反应，对宿主或细菌有利。
